Beta Drugs Ltd. · NSE:BETA
Beta Drugs — H1 2022-23 Earnings Presentation
22 slides from Beta Drugs's earnings presentation, Oct 28, 2022
Slide 1: Investor Presentation H1' 2022-23
Investor Presentation H1’ 2022-23
Slide 2: Dedicated to Oncology
Dedicated to Oncology 12 years of Oncology FFTLs
Slide 3: Healthy growth in Revenue & Profit
Healthy growth in Revenue & Profit REVENUE Growth H1’22 H1’23 FY’21 FY’22 over (Rs Cr) (Rs Cr) H1’22 Total revenue 116.12 183.83 88.1 112.39 28% EBITDA 25.24 43.46 20.50 27.13 32% EBITDA % 21.7% 23.6% 23.3% 24.1% 87 bps PAT 11.72 24.83 11.75 15.83 35% PAT % 10.1% 13.5% 13.3% 14.1% 79 bps 3
Slide 4: Financial Performance
Financial Performance ------------------------------------- % EBITDA % Operating/ EBIT 24.1% 23.6% 19.7% 19.8% 16.0% 15.8% 21.7% 20.2% FY'20 FY'21 FY'22 H1'22-23 FY'20 FY'21 FY'22 H1'22-23 ---------------------------------------------------------------------------------------------------------------
Slide 5: Solvency Ratio
Solvency Ratio --------------------------------- 0.21 Debt ratio Debt to equity ratio 0.14 0.39 0.13 0.11 0.25 0.21 0.18 FY'20 FY'21 FY'22 H1'22-23 FY'20 FY'21 FY'22 H1 22-23 -----------------------------------------------------------------------------------------------------------------------------
Slide 6: Healthy Growth across all verticals in H1'23 (Y-O-Y)
Healthy Growth across all verticals in H1’23 (Y-O-Y) Domestic Own brand International 42 % revenue growth 58 % revenue growth 119 % revenue growth 5 % revenue growth
Slide 7: Key Business Highlights in H1'23
Key Business Highlights in H1’23 ❖ Strengthening the Haematology basket with the launch of Carfimib (Carfilzomib) ❖ Major breakthrough is INVIMA accreditation. ❖ Top 10 brands contributing 50% of sales It will open the doors for business opportunities ❖ Added 200+ new prescribers in LatAm ❖ Increase
Slide 8: Unique value propositions give us competitive edge
Unique value propositions give us competitive edge State of Art Diversified Oncology Manufacturing facilities Backwardly Integrated portfolio Strong Future pipeline BDL is among the few Rich product pipeline of Manufacturing facilities companies that work dedicated to Oncology 23 products across the
Slide 9: Formulations and API Plant
Formulations and API Plant BETA DRUGS LTD. ADLEY FORMULATION PVT LTD. ADLEY LAB LTD. : API Plant Address: Address: Address: KHARUNI-LODHI MAJRA VILLAGE KOTLA,P.O. BAROTIWALA,SOLAN D-27 FOCAL POINT DERABASSI SAS Nagar ROAD,VILL.NANDPUR,BADDI-174101 (HP)-174103 PUNJAB DIST-SOLAN (HP) WHO-GMP facility
Slide 10: Making complex Oncology products accessible to all Indian cancer patients
Making complex Oncology products accessible to all Indian cancer patients Building Healthier world By providing affordable & With focus on R&D quality Oncology medicines With 2 formulations & 1 API state-of- 63 products 10 First few to launch (FFTL) the-art manufacturing facilities 110 SKUs products
Slide 11: Domestic Own Brand
Domestic Own Brand Soli ADSUNIB anteaP BEXINIB CAPAD ADOXI ADPLATIN Tumor Adlante Sct -RTU —_AMGICIN ADGEF ERLOTAD =TEMOZAD HER-TINIB ADTRINIB ADCARB ADCIST Lapa Tables 250mg Seratelb Tablets 200 mg Garopiint150/650m¢ Capt RT 1OBOMg AB-PACLI ADPAXIL EISTENT LETRAFEM ADNAST ADRICIN Paclitaxel Protein
Slide 12: Strong In-House API Development
Strong In-House API Development
Slide 13: Established trust among CMO partners
Established trust among CMO partners Trusted Partners We value our CMO partners Sustained growth Important clients
Slide 14: New products development are pivotal to our growth
New products development are pivotal to our growth No of the brands launched 8 9 5 3 brands are expected to launch in H2 2022-23 1 Expertise in NDDS (New Drug Delivery System) 2019-20 2020-21 2021-22 2022-23 Proven experience in managing complex product development- Azacitidine Oral, Ready to Use Ge
Slide 15: FUTURE ROADMAP: ENTER, EXPAND & EXCEL
FUTURE ROADMAP: ENTER, EXPAND & EXCEL The Company aims to establish its presence and expand in Indian & international markets ENTER Expand EXCEL Keep on pursuing various opportunities The management aims to foray into Increase new product registration to capture the incremental market European, Lati
Slide 16: Road map for Domestic branded market
Road map for Domestic branded market Strengthen product basket Increase customer base Market penetration 25 % increase in customer base through: • Increasing presence in tier 2 & tier 3 cities • New corporate & private hospital entries. • Entry into major Govt. institutes • Strengthening Hemato & Ur
Slide 17: Geographical Expansion
Geographical Expansion The first major breakthrough: Received INVIMA (Colombia) accreditation Application filed Mexico Brazil Beta aims to enter aggressively into Brazil, Mexico, Colombia, and other LatAm market. These are the top 3 largest markets in LatAm (constitute ~70% of the Oncology market)
Slide 18: Geographical Expansion
Geographical Expansion LatAm ASIA No. of targeted countries: 18 No. of targeted countries: 15 Total dossiers submission plan Total dossiers submission in next 2 years: 110 plan in next 2 years: 180 AFRICA CIS No. of targeted countries: 17 No. of targeted countries: 7 Total dossiers submission plan i
Slide 19: API Expansion Plan
API Expansion Plan • Foraying into the European market • 1st CEP going to file by Jan’23 • In FY’24 planning to file 4 more CEPs Geographical • Focus on export in the nonregulated, semi- expansion regulated, and regulated market Increase • Plant audit by major pharmaceutical presence in companies fo
Slide 20: Foraying into Cosmetic Dermatology
Foraying into Cosmetic Dermatology Total Market :~ 12000 Cr. Aesthetic Medical Market size: 9000Cr Market size: 3000Cr Fast growing market: 11% CAGR Easy to fill market gap with innovative products Low entry barrier Product differentiation Product Acceptance Future Plan Plan to establish new Science
Slide 21: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 22: THANK YOU
THANK YOU Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India)